Preclinical studies demonstrate that sPD-1 delivery via gene transfer or systemic administration disrupts PD-L1-mediated T-cell inhibition, including blocking interactions with B7-1 (CD80), which enhances anti-tumor immunity [18,70]. Here, CD80 is linked to neoplasm.